Each year, the American Thyroid Association® (ATA®) honors clinicians, academicians and early career researchers who have made outstanding contributions in thyroidology. These awards honor both professional achievements and contributions to ATA.
Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Thyroid cancers (TC) are driven by a handful of genetic alterations. Papillary TC primarily harbors mutations involving BRAF, RAS or RET genes.
The parathyroids are small, oval-shaped glands that tightly regulate serum calcium levels through the production of parathyroid hormone (PTH), which stimulates the release of calcium from bone, increased GI absorption of calcium, and decreased renal excretion of calcium.
Medullary thyroid cancer (MTC) is a rare thyroid malignancy and considered a neuroendocrine type of tumor.
Thyroid thermal ablative techniques in North America has been on the rise. These techniques have emerged as compelling alternatives to surgery for benign nodular disease.
There are limited number of studies that have examined patients preferences concerning treatment options for patients with thyroid cancer.
Endocrine disruptors, like triclosan can affect the action of endocrine glands, including the thyroid gland.
It is important for pediatricians to understand how TFTs are affected by obesity, when to order thyroid function tests, and when to refer.
Thyroid hormone replacement is a critical element in the overall management of patients with thyroid cancer.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.© 2025 American Thyroid Association.
